Agilent Technologies, 1 Yishun Avenue 7, Singapore 768923, Republic of Singapore.
Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, Centros #06-01, Singapore 138668, Republic of Singapore.
Nanomedicine. 2024 Jun;58:102745. doi: 10.1016/j.nano.2024.102745. Epub 2024 Mar 16.
Understanding the stability of mRNA loaded lipid nanoparticles (mRNA-LNPs) is imperative for their clinical development. Herein, we propose the use of size-exclusion chromatography coupled with dual-angle light scattering (SEC-MALS) as a new approach to assessing mRNA-LNP stability in pure human serum and plasma. By applying a dual-column configuration to attenuate interference from plasma components, SEC-MALS was able to elucidate the degradation kinetics and physical property changes of mRNA-LNPs, which have not been observed accurately by conventional dynamic light scattering techniques. Interestingly, both serum and plasma had significantly different impacts on the molecular weight and radius of gyration of mRNA-LNPs, suggesting the involvement of clotting factors in desorption of lipids from mRNA-LNPs. We also discovered that a trace impurity (~1 %) in ALC-0315, identified as its O-tert-butyloxycarbonyl-protected form, greatly diminished mRNA-LNP stability in serum. These results demonstrated the potential utility of SEC-MALS for optimization and quality control of LNP formulations.
了解负载 mRNA 的脂质纳米粒(mRNA-LNPs)的稳定性对于其临床开发至关重要。在此,我们提出使用尺寸排阻色谱法结合双角度光散射(SEC-MALS)作为一种新方法来评估纯人血清和血浆中的 mRNA-LNP 稳定性。通过应用双柱配置来减弱血浆成分的干扰,SEC-MALS 能够阐明 mRNA-LNP 的降解动力学和物理性质变化,而传统的动态光散射技术无法准确观察到这些变化。有趣的是,血清和血浆对 mRNA-LNP 的分子量和回转半径有显著不同的影响,这表明凝血因子参与了 mRNA-LNP 中脂质的解吸。我们还发现,ALC-0315 中的痕量杂质(约 1%),被鉴定为其 O-叔丁氧羰基保护形式,大大降低了 mRNA-LNP 在血清中的稳定性。这些结果表明 SEC-MALS 可用于优化和控制 LNP 制剂的质量。